Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF -1-
August 27, 2001
- Genzyme to Switch to Quatro Test for Maternal Serum Testing
August 27, 2001
- Contract MRs Are Being Rapidly Accepted: Apo Plus Station President
August 27, 2001
- Korosho to Start Model Project to Set Up Network of Electronic Medical Charts
August 27, 2001
- BULLETIN
August 27, 2001
- BUSINESS NEWS IN BRIEF -1-
August 27, 2001
- Errors in Medical Bills Related to Patients' ID Increasing
August 27, 2001
- REGULATORY NEWS IN BRIEF -2-
August 27, 2001
- BUSINESS NEWS IN BRIEF -2-
August 27, 2001
- Number of Long-term Care Beds Up to 5,837
August 27, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
August 27, 2001
- IFN Alphacon-1 Recommended for Approval
August 27, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
August 27, 2001
- Majority of Patients Want to See Their Own Medical Records: JNA Survey
August 27, 2001
- Reform Promotion Headquarters Proposes Reform of Drug Organization
August 27, 2001
- Goldshield Group Plans Advances into Japanese Market
August 27, 2001
- Banyu, Kyorin to Launch LT Antagonist
August 27, 2001
- Ceiling on Natural Increase in Social Security-related Budget Set at \700 Bil.
August 27, 2001
- Further Deregulation Needed for Nutritional Supplements: US Embassy Tokyo
August 27, 2001
- Korosho Prepares for Full Discussions on Healthcare Reform from September
August 27, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…